JP2008523073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523073A5 JP2008523073A5 JP2007545584A JP2007545584A JP2008523073A5 JP 2008523073 A5 JP2008523073 A5 JP 2008523073A5 JP 2007545584 A JP2007545584 A JP 2007545584A JP 2007545584 A JP2007545584 A JP 2007545584A JP 2008523073 A5 JP2008523073 A5 JP 2008523073A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- medicament according
- cancer
- her2
- tumor sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 44
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 239000000523 sample Substances 0.000 claims 20
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 15
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 15
- 102000005962 receptors Human genes 0.000 claims 12
- 108020003175 receptors Proteins 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 10
- 101800001382 Betacellulin Proteins 0.000 claims 9
- 102100029837 Probetacellulin Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 102000007299 Amphiregulin Human genes 0.000 claims 8
- 108010033760 Amphiregulin Proteins 0.000 claims 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical group FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 5
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 230000026731 phosphorylation Effects 0.000 claims 4
- 238000006366 phosphorylation reaction Methods 0.000 claims 4
- 239000004010 HER dimerization inhibitor Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000003752 polymerase chain reaction Methods 0.000 claims 3
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 238000011529 RT qPCR Methods 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000012188 paraffin wax Substances 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 101800000155 Epiregulin Proteins 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102100025498 Proepiregulin Human genes 0.000 claims 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 238000005734 heterodimerization reaction Methods 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63394104P | 2004-12-07 | 2004-12-07 | |
| PCT/US2005/044247 WO2006063042A2 (en) | 2004-12-07 | 2005-12-06 | Selecting patients for therapy with a her inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008523073A JP2008523073A (ja) | 2008-07-03 |
| JP2008523073A5 true JP2008523073A5 (cg-RX-API-DMAC7.html) | 2009-01-29 |
Family
ID=36177671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007545584A Pending JP2008523073A (ja) | 2004-12-07 | 2005-12-06 | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
Country Status (14)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AU2001264696B2 (en) | 2000-05-19 | 2007-01-04 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
| ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| ZA200701234B (en) * | 2004-07-22 | 2008-12-31 | Genentech Inc | HER2 antibody composition |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| CA2592177A1 (en) * | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| CA2596133C (en) * | 2005-02-23 | 2016-11-15 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| WO2007025044A2 (en) * | 2005-08-24 | 2007-03-01 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| JP2007135581A (ja) * | 2005-10-20 | 2007-06-07 | Japan Science & Technology Agency | 自己免疫性血小板減少性紫斑病（ｉｔｐ）患者の血液細胞特異的遺伝子群 |
| US20080038271A1 (en) * | 2006-06-05 | 2008-02-14 | Amler Lukas C | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
| EP2518508A1 (en) * | 2006-11-28 | 2012-10-31 | U3 Pharma GmbH | Activated HER3 as a marker for predicting therapeutic efficacy |
| US7825127B2 (en) * | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
| CN101711284A (zh) * | 2007-01-25 | 2010-05-19 | 达娜-法勃肿瘤研究所 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
| CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
| EP2592156B1 (en) * | 2007-06-08 | 2016-04-20 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| WO2009023265A1 (en) | 2007-08-14 | 2009-02-19 | Ludwig Institute For Cancer Research | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
| WO2009026705A1 (en) * | 2007-08-24 | 2009-03-05 | The University Of Western Ontario | Method of diagnosing and treating osteoarthritis |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| WO2010006027A1 (en) | 2008-07-08 | 2010-01-14 | George Mason Intellectual Properties, Inc. | Phosphorylated c-erbb2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer |
| CN102753193A (zh) | 2008-10-31 | 2012-10-24 | 比奥根艾迪克Ma公司 | Light靶向分子及其用途 |
| EP2513148B1 (en) * | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2 antibodies and their uses |
| SG183532A1 (en) | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| CA2800769C (en) | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| CN107253992B (zh) | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| MX347981B (es) | 2010-11-01 | 2017-05-22 | Symphogen As | Composicion de anticuerpos pan-her. |
| CN103796677B (zh) | 2011-04-20 | 2019-08-16 | 健玛保 | 针对her2和cd3的双特异性抗体 |
| CA2851314A1 (en) * | 2011-10-06 | 2013-04-11 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
| PT4403228T (pt) | 2011-10-14 | 2025-10-07 | Hoffmann La Roche | Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| JP6602746B2 (ja) * | 2013-03-15 | 2019-11-06 | カポン、ダニエル・ジェイ． | 非ペプチジル結合を含むハイブリッド免疫グロブリン |
| US9815904B2 (en) | 2013-04-16 | 2017-11-14 | Genetech, Inc. | Pertuzumab variants and evaluation thereof |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| ES2932285T3 (es) | 2014-03-14 | 2023-01-17 | Biomolecular Holdings Llc | Compuestos útiles en la preparación de inmunoglobulina híbrida que contiene una unión distinta de peptidilo |
| KR20160141857A (ko) | 2014-04-25 | 2016-12-09 | 제넨테크, 인크. | 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법 |
| CN108027360A (zh) * | 2015-05-29 | 2018-05-11 | 爱科谱迅病理研究公司 | 用于最优癌症治疗的定量Her2蛋白质 |
| PT3302551T (pt) | 2015-05-30 | 2024-08-21 | H Hoffnabb La Roche Ag | Métodos de tratamento do cancro da mama metastático positivo para her2 não tratado previamente |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| GB201611580D0 (en) * | 2016-07-01 | 2016-08-17 | Aslan Pharmaceuticals Pte Ltd | Method |
| CA3040913A1 (en) | 2016-11-04 | 2018-05-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
| US20180221481A1 (en) | 2016-12-28 | 2018-08-09 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
| LT3570884T (lt) | 2017-01-17 | 2020-12-10 | Genentech, Inc. | Poodinės her2 antikūnų kompozicijos |
| JP6992081B2 (ja) | 2017-03-02 | 2022-02-03 | ジェネンテック， インコーポレイテッド | Ｈｅｒ２陽性乳癌のアジュバント治療 |
| WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| MX2022015884A (es) | 2020-06-29 | 2023-04-03 | Genentech Inc | Combinacion de dosis fija de pertuzumab mas trastuzumab. |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5824311A (en) * | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| CA2103059C (en) * | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| WO1999048527A1 (en) * | 1998-03-27 | 1999-09-30 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
| DE69907439T3 (de) * | 1998-05-06 | 2014-01-02 | Genentech, Inc. | Reinigung von proteinen durch ionenaustauschchromatographie |
| US6573043B1 (en) * | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| AU782325B2 (en) * | 1999-05-14 | 2005-07-21 | Genentech Inc. | Treatment with anti-ErbB2 antibodies |
| MXPA01013395A (es) * | 1999-06-25 | 2003-09-04 | Genentech Inc | Tratamiento de cancer de prostata con anticuerpos anti-erbb2. |
| US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) * | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| BRPI0012198B8 (pt) * | 1999-06-25 | 2021-05-25 | Genentech Inc | anticorpos humanizados, composição e imunoconjugado |
| EP2110138A1 (en) * | 1999-08-27 | 2009-10-21 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| AU2001264696B2 (en) * | 2000-05-19 | 2007-01-04 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
| US20030190689A1 (en) * | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
| US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| AU2003273218C1 (en) * | 2002-07-15 | 2019-01-17 | F. Hoffmann - La Roche Ag | Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies |
| US20040013297A1 (en) * | 2002-07-18 | 2004-01-22 | Roger Lo | Method for performing color gamut compression |
| CA2500255A1 (en) * | 2002-10-01 | 2004-04-29 | Epigenomics Ag | Method and nucleic acids for the treatment of breast cell proliferative disorders |
| JP4606879B2 (ja) * | 2002-11-15 | 2011-01-05 | ジェノミック ヘルス， インコーポレイテッド | Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング |
| US20040258685A1 (en) * | 2002-11-21 | 2004-12-23 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies |
| US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| CA2530738C (en) * | 2003-06-24 | 2020-01-21 | Genomic Health, Inc. | Prediction of likelihood of cancer recurrence |
| JP4969440B2 (ja) * | 2004-04-08 | 2012-07-04 | デビッド， ビー． エイガス， | 疼痛治療のためのＥｒｂＢアンタゴニスト |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| ZA200701234B (en) * | 2004-07-22 | 2008-12-31 | Genentech Inc | HER2 antibody composition |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| CA2592177A1 (en) * | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| CA2596133C (en) * | 2005-02-23 | 2016-11-15 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| TW200642695A (en) * | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| TW200812615A (en) * | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| US20080038271A1 (en) * | 2006-06-05 | 2008-02-14 | Amler Lukas C | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
| EP2441472B1 (en) * | 2006-08-21 | 2015-06-10 | F. Hoffmann-La Roche AG | Tumor therapy with an anti-VEGF antibody |
-
2005
- 2005-12-06 JP JP2007545584A patent/JP2008523073A/ja active Pending
- 2005-12-06 AU AU2005314127A patent/AU2005314127A1/en not_active Abandoned
- 2005-12-06 EP EP05853228A patent/EP1825001A2/en not_active Withdrawn
- 2005-12-06 ZA ZA200704796A patent/ZA200704796B/xx unknown
- 2005-12-06 CA CA002587519A patent/CA2587519A1/en not_active Abandoned
- 2005-12-06 MX MX2007006529A patent/MX2007006529A/es not_active Application Discontinuation
- 2005-12-06 BR BRPI0518086-4A patent/BRPI0518086A/pt not_active IP Right Cessation
- 2005-12-06 KR KR1020077012834A patent/KR20070085855A/ko not_active Withdrawn
- 2005-12-06 US US11/295,229 patent/US20060121044A1/en not_active Abandoned
- 2005-12-06 CN CNA2005800478629A patent/CN101115849A/zh active Pending
- 2005-12-06 WO PCT/US2005/044247 patent/WO2006063042A2/en not_active Ceased
- 2005-12-06 RU RU2007125644/13A patent/RU2007125644A/ru not_active Application Discontinuation
- 2005-12-07 AR ARP050105126A patent/AR051524A1/es not_active Application Discontinuation
-
2007
- 2007-07-05 NO NO20073487A patent/NO20073487L/no not_active Application Discontinuation
-
2008
- 2008-05-01 US US12/113,802 patent/US20080317753A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008523073A5 (cg-RX-API-DMAC7.html) | ||
| Nahta et al. | Herceptin: mechanisms of action and resistance | |
| Jeon et al. | Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction | |
| Asiedu et al. | AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells | |
| Boku | HER2-positive gastric cancer | |
| Wilken et al. | Primary trastuzumab resistance: new tricks for an old drug | |
| Karamouzis et al. | Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors | |
| RU2007125644A (ru) | Отбор пациентов для терапии ингибитором her | |
| Chen et al. | MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells | |
| Yeon et al. | Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer | |
| Yan et al. | HER2 aberrations in cancer: implications for therapy | |
| LoRusso et al. | Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors | |
| Takikita et al. | Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma | |
| Chiu et al. | HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients | |
| Guo et al. | L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival | |
| Meetze et al. | Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models | |
| Menyhart et al. | A comprehensive outline of trastuzumab resistance biomarkers in HER2 overexpressing breast cancer | |
| Bailey et al. | NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth | |
| Jacobi et al. | ErbB family signalling: a paradigm for oncogene addiction and personalized oncology | |
| Meulendijks et al. | Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity | |
| Murthy et al. | Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer | |
| Law et al. | Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability | |
| Sanz-Moreno et al. | RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer | |
| Zardavas et al. | Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015 | |
| Wang et al. | The role of HER3 in gastric cancer |